Valuation: Adimmune Corporation

Market Cap 7.44B 232M 203M 187M 173M 328M 22.11B 333M 2.23B 878M 10.89B 870M 851M 37.44B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 8.05B 251M 219M 202M 187M 355M 23.93B 361M 2.42B 950M 11.79B 942M 921M 40.52B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 week-0.84%
Current month+0.28%
1 month-0.84%
3 months-3.81%
6 months-11.53%
Current year-6.86%
1 week 17.5
Extreme 17.5
18.2
1 month 16.8
Extreme 16.8
18.2
Current year 16.8
Extreme 16.8
21.5
1 year 16.75
Extreme 16.75
22.5
3 years 15.9
Extreme 15.9
38
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.84%+7.95%-51.51% 232M
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-49.30%-53.47% 40.94B
+0.12%-7.85%+47.16%-29.27% 29.4B
-10.83%-14.41%+99.15%-44.54% 27.09B
-1.53%-0.13%+65.92%+88.58% 23.32B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
Average -1.24%-2.80%+33.93%+47.83% 32B
Weighted average by Cap. -1.36%-2.83%+30.48%+49.31%

Financials

2024 2025
Net sales 1.56B 48.51M 42.43M 39.14M 36.15M 68.59M 4.63B 69.75M 468M 184M 2.28B 182M 178M 7.84B 1.4B 43.67M 38.2M 35.23M 32.54M 61.74M 4.16B 62.78M 421M 165M 2.05B 164M 160M 7.05B
Net income -243M -7.56M -6.62M -6.1M -5.64M -10.69M -721M -10.87M -72.91M -28.63M -355M -28.4M -27.78M -1.22B -240M -7.47M -6.54M -6.03M -5.57M -10.57M -713M -10.75M -72.05M -28.29M -351M -28.06M -27.45M -1.21B
Net Debt 140M 4.35M 3.8M 3.51M 3.24M 6.15M 415M 6.25M 41.92M 16.46M 204M 16.33M 15.97M 702M 612M 19.08M 16.69M 15.39M 14.22M 26.97M 1.82B 27.43M 184M 72.22M 896M 71.63M 70.07M 3.08B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
09/07/26 NT$17.65 0.00% 541,637
08/07/26 NT$17.65 -0.28% 671,787
07/07/26 NT$17.70 -1.39% 908,800
06/07/26 NT$17.95 +0.84% 1,362,851
03/07/26 NT$17.80 +2.30% 1,973,014
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock